New research suggests manufacturers of newly developed antidepressant drugs have become more forthcoming about clinical trials that don’t pan out. While the new findings are encouraging, they still hint at a fundamental shortcoming in medicine: A reliance of studies selectively reported in scientific literature, as opposed to the unvarnished results of clinical trials reported to the Food and Drug Administration.